acebutolol has been researched along with ferlixit in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arneth, B; Bornstein, SR; Fischer, S; Julius, U; Schatz, U; Siegels, D; Siegert, G | 1 |
| Biggar, P; Hahn, KM | 1 |
| Münch, HG; Potthoff, SA | 1 |
| Arneth, B; Bornstein, SR; Heigl, F; Hettich, R; Illigens, BM; Julius, U; Prophet, H; Ramlow, W; Schatz, U; Siegels, D; Siegert, G; Siepmann, T | 1 |
| Connor, JR; Nixon, AM; Perno, JR; Webb, B; Zhang, X | 1 |
| Marmifero, M; Meregaglia, M; Rognoni, C; Tarricone, R; Venturini, S | 1 |
| Crumbliss, AL; Gupta, A; Pratt, RD | 1 |
| Fell, LH; Fliser, D; Heine, GH; Rotter, B; Seiler-Mußler, S; Sellier, AB; Sester, M; Winter, P; Zawada, AM | 1 |
| Coyne, DW; Daloul, R; Pandey, R | 1 |
| Auerbach, M; Macdougall, I | 1 |
| Caccamo, G; Di Franco, A; Giallauria, F; Nugara, C; Sarullo, FM; Sarullo, S; Vitale, G; Vitale, S | 1 |
| Albanesi, M; Caiaffa, MF; Di Bona, D; Di Girolamo, A; Loconte, F; Macchia, L | 1 |
5 review(s) available for acebutolol and ferlixit
| Article | Year |
|---|---|
[Importance of the different i.v. iron generations for everyday medical practice].
Topics: Anemia, Iron-Deficiency; Disaccharides; Dose-Response Relationship, Drug; Drug Substitution; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Structure-Activity Relationship; Treatment Outcome | 2013 |
[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Topics: Administration, Oral; Anaphylaxis; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Oxidative Stress; Renal Dialysis | 2013 |
Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.
Topics: Administration, Intravenous; Chemistry, Pharmaceutical; Ferric Compounds; Hemoglobins; Humans; Iron Deficiencies; Maltose; Randomized Controlled Trials as Topic | 2016 |
Iron Treatment Strategies in Dialysis-Dependent CKD.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Renal Dialysis; Transferrin | 2016 |
The available intravenous iron formulations: History, efficacy, and toxicology.
Topics: Anemia; Drug Compounding; Ferric Compounds; Ferrosoferric Oxide; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Maltose; Renal Dialysis | 2017 |
1 trial(s) available for acebutolol and ferlixit
| Article | Year |
|---|---|
Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Blood Component Removal; Chemistry, Pharmaceutical; Drug Administration Schedule; Dyslipidemias; Female; Ferric Compounds; Ferritins; Germany; Hematinics; Humans; Infusions, Intravenous; Lipoproteins; Male; Maltose; Middle Aged; Time Factors; Transferrin; Treatment Outcome | 2013 |
6 other study(ies) available for acebutolol and ferlixit
| Article | Year |
|---|---|
TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Blood Component Removal; Drug Administration Schedule; Female; Ferric Compounds; Ferritins; Germany; Hematinics; Humans; Hyperlipoproteinemias; Infusions, Intravenous; Iron; Lipoproteins, LDL; Male; Maltose; Middle Aged; Prospective Studies; Time Factors; Transferrin; Treatment Outcome | 2015 |
Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Topics: Animals; Cation Transport Proteins; Cell Line; Cell Survival; Disaccharides; Epithelial Cells; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hepcidins; Humans; Iron; Iron-Dextran Complex; Kidney; Lipid Peroxidation; Macrophages, Peritoneal; Maltose; Oxidative Stress; Primary Cell Culture; Rats; Tumor Necrosis Factor-alpha | 2015 |
Ferrous iron content of intravenous iron formulations.
Topics: Administration, Intravenous; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Ferrous Compounds; Glucaric Acid; Iron-Dextran Complex; Maltose | 2016 |
Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Topics: Anemia, Iron-Deficiency; Case-Control Studies; Cell Differentiation; Dendritic Cells; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Iron Compounds; Macrophages; Maltose; MicroRNAs; Monocytes; Phagocytosis | 2016 |
Effect of intravenous iron replacement therapy on exercise capacity in iron deficient anemic patients after cardiac surgery.
Topics: Aged; Anemia, Iron-Deficiency; Cardiac Surgical Procedures; Exercise Tolerance; Female; Ferric Compounds; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Retrospective Studies; Treatment Outcome | 2020 |
Desensitization in Iron Product Allergy.
Topics: Adult; Anemia, Iron-Deficiency; Chlorpheniramine; Dexamethasone; Female; Ferric Compounds; Hematinics; Humans; Hypersensitivity; Iron; Maltose; Middle Aged; Skin Tests | 2020 |